The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
November 20th 2024
Bimekizumab-bkzx is the first and only approved medication that targets both interleukin (IL) 17F and IL-17A.
November 13th 2024
As Chemotherapy Drug Shortage Continues, Unimaginable Decisions and Lacking Accountability Reign
July 24th 2023Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.
Read More
Confirmatory PAPILLON Study Supports Amivantamab-vmjw For Patients with Severe Lung Cancer Mutation
July 19th 2023The 5-year survival rate for patients with exon 20 insertion EFGR mutation is 8% in the frontline setting, worse than the survival rate of the 2 most common types of EGFR mutations in patients with advanced or metastatic non-small cell lung cancer.
Read More
Pediatric Medication Studies: A New Challenge for Institutional Review Boards, Ethics Committees
July 10th 2023Institutional review boards and ethics committees have seen it as their main task in the past few decades to protect children from questionable studies; however, they are faced with a new challenge with pediatric drug development.
Read More
Have Children Truly Ever Been ‘Therapeutic Orphans?’
June 16th 2023Imposing the FDA on-label/off-label framework on administratively defined "children" resulted in a regulatory demand for pediatric studies that had no basis in clinical medicine, with the exception of the small group of preterm newborns.
Read More
Patient Case Study: A Rare Neurological Disease Diagnostic Journey
June 8th 2023Neuromyelitis optica spectrum disorder is an autoimmune disease characterized by severe attacks of optic neuritis and/or myelitis, leading to possible visual loss, paralysis, cognitive impairment, sensory deficits, bladder dysfunction, and even mortality.
Read More